Heusden, Belgium

Rosalinde Van Lipzip

This inventor holds 1 USPTO granted patent. Top assignee: Bayer Intellectual Property Gmbh. Active years: 2016.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rosalinde Van Lipzip: Innovator in Nucleic Acid Technology

Introduction

Rosalinde Van Lipzip is a prominent inventor based in Heusden, Belgium. She has made significant contributions to the field of biotechnology, particularly in the area of nucleic acid molecules. Her innovative work has led to the development of novel solutions that have the potential to impact various applications in agriculture and beyond.

Latest Patents

Rosalinde holds 1 patent for her invention titled "Truncated alternan sucrase coding nucleic acid molecules." This invention relates to nucleic acid molecules that code for a truncated alternan sucrase. The invention further encompasses truncated alternan sucrases, vectors, host cells, and plant cells transformed with the described nucleic acid molecules. Additionally, it introduces novel alternan polymers with advantageous properties and methods for their production.

Career Highlights

Rosalinde is associated with Bayer Intellectual Property GmbH, where she continues to advance her research and development efforts. Her work at Bayer has allowed her to collaborate with leading experts in the field and contribute to groundbreaking innovations.

Collaborations

Rosalinde has worked closely with Claus Frohberg, a fellow innovator in her field. Their collaboration has fostered the exchange of ideas and expertise, further enhancing the impact of their research.

Conclusion

Rosalinde Van Lipzip is a trailblazer in the field of nucleic acid technology, with her innovative patent showcasing her commitment to advancing biotechnology. Her contributions are poised to make a lasting impact in various applications, particularly in agriculture.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…